|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0008838,
umls-concept:C0016360,
umls-concept:C0023413,
umls-concept:C0045093,
umls-concept:C0205088,
umls-concept:C0205195,
umls-concept:C0282461,
umls-concept:C0332283,
umls-concept:C0346976,
umls-concept:C1274040,
umls-concept:C1519249,
umls-concept:C1555029
|
|
pubmed:issue |
11
|
|
pubmed:dateCreated |
2010-10-15
|
|
pubmed:abstractText |
Gemcitabine is the standard chemotherapy for patients with metastatic pancreatic adenocarcinoma. Although the 5-fluorouracil (5FU), folinic acid and cisplatin combination (LV5FU2-CDDP) is an option, the optimal order of the regimens must be determined. The first strategic phase III trial comparing LV5FU2-CDDP followed by gemcitabine versus gemcitabine followed by LV5FU2-CDDP was conducted.
|
|
pubmed:commentsCorrections |
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Nov
|
|
pubmed:issn |
1468-3288
|
|
pubmed:author |
pubmed-author:BedenneLaurentL,
pubmed-author:BonnetainFrankF,
pubmed-author:CattanStéphaneS,
pubmed-author:ChauffertBrunoB,
pubmed-author:DahanLaetitiaL,
pubmed-author:Fédération Francophone de Cancérologie Digestive,
pubmed-author:GasmiMohamedM,
pubmed-author:HammelPascalP,
pubmed-author:LegouxJean-LouisJL,
pubmed-author:MichelPierreP,
pubmed-author:MitryEmmanuelE,
pubmed-author:PhelipJean-MarcJM,
pubmed-author:RaoulJean-LucJL,
pubmed-author:RougierPhilippeP,
pubmed-author:SeitzJean-FrançoisJF,
pubmed-author:YchouMarcM
|
|
pubmed:issnType |
Electronic
|
|
pubmed:volume |
59
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1527-34
|
|
pubmed:dateRevised |
2011-1-24
|
|
pubmed:meshHeading |
pubmed-meshheading:20947887-Adenocarcinoma,
pubmed-meshheading:20947887-Adult,
pubmed-meshheading:20947887-Aged,
pubmed-meshheading:20947887-Aged, 80 and over,
pubmed-meshheading:20947887-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:20947887-Cisplatin,
pubmed-meshheading:20947887-Deoxycytidine,
pubmed-meshheading:20947887-Disease Progression,
pubmed-meshheading:20947887-Drug Administration Schedule,
pubmed-meshheading:20947887-Female,
pubmed-meshheading:20947887-Fluorouracil,
pubmed-meshheading:20947887-France,
pubmed-meshheading:20947887-Humans,
pubmed-meshheading:20947887-Leucovorin,
pubmed-meshheading:20947887-Male,
pubmed-meshheading:20947887-Middle Aged,
pubmed-meshheading:20947887-Pancreatic Neoplasms,
pubmed-meshheading:20947887-Survival Analysis,
pubmed-meshheading:20947887-Treatment Outcome
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Combination 5-fluorouracil, folinic acid and cisplatin (LV5FU2-CDDP) followed by gemcitabine or the reverse sequence in metastatic pancreatic cancer: final results of a randomised strategic phase III trial (FFCD 0301).
|
|
pubmed:affiliation |
Service d'Oncologie Digestive, Pôle Oncologie-Spécialités, CHU Timone, Marseille cedex 5, France. laetitia.dahan@mail.ap-hm.fr
|
|
pubmed:publicationType |
Journal Article,
Randomized Controlled Trial,
Multicenter Study,
Clinical Trial, Phase III
|
